XOMA NASDAQ
XOMA Royalty Corp.
1W: -0.4%
1M: +6.2%
3M: +62.0%
YTD: +49.4%
1Y: +57.2%
3Y: +104.0%
5Y: +39.8%
$41.65
-0.17 (-0.41%)
Weekly Expected Move ±6.2%
$37
$39
$42
$44
$47
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider+$2.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$522.3M
52W Range22.29-42.81
Volume124,509
Avg Volume216,566
Beta0.90
Dividend$2.16
Analyst Ratings
Company Info
CEOOwen Hughes Jr.
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date1986-06-06
Websitexoma.com
2200 Powell Street
EmeryVille, CA 94608
US
EmeryVille, CA 94608
US
510 204 7200
About XOMA Royalty Corp.
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Latest News
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | C-Conversion | 2,313,000 | $4.03 | 2026-05-14 |
| BVF PARTNERS L P/IL | C-Conversion | 1,506,000 | $4.03 | 2026-05-14 |
| BVF PARTNERS L P/IL | C-Conversion | 772,000 | $4.03 | 2026-05-14 |
| BVF PARTNERS L P/IL | C-Conversion | 412,000 | $4.03 | 2026-05-14 |
| BVF PARTNERS L P/IL | C-Conversion | 772 | $4.03 | 2026-05-14 |